SOPHIA ANTIPOLIS, France – April 3rd, 2025 │ March 11th, Bristol Myers Squibb (BMS) announced a definitive merger agreement to acquire all of the outstanding shares of 2seventy bio for a total equity value of approximately $286 million. The company 2seventy bio decided to focus exclusively on Abecma which was the first B cell maturation[…]
SOPHIA ANTIPOLIS, France – March 7, 2025 │ A few days ago, Regeneron decided to no longer seek accelerated approval of odronextamab, a bispecific antibody (bsAb) CD20 x CD3, for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, the company is continuing to pursue this approval for follicular lymphoma (FL), with an FDA[…]
SOPHIA ANTIPOLIS, France – February 4th, 2025 (last update 10th April, 2025) │ Advancements in oncology have consistently pushed the boundaries of therapeutic innovation, particularly in the realm of immunotherapy. BioNTech’s BNT327, a bispecific antibody targeting vascular endothelial growth factor (VEGF) and Programmed death-ligand 1 (PD-L1), represents a cutting-edge approach to treating difficult cancers such[…]
SOPHIA ANTIPOLIS, France – February 04, 2025 │ KnowMade actively tracks therapeutic mRNA innovations as part of its Therapeutic mRNA patent monitoring services. What’s new today? CHMP Recommends Approval of KOSTAIVE® (ARCT-154) EMA opinion The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval[…]